Biologics have transformed the treatment of immune-mediated inflammatory diseases such
as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars—biologic …

Background: Anti-tumour necrosis factor-alpha (anti-TNF) antagonists have been the
mainstay in the treatment of inflammatory bowel diseases (IBDs) for over 20 years …

Background & aims This study compared pharmacokinetics, symptomatic and endoscopic
efficacy, safety, and immunogenicity of a subcutaneous formulation of the infliximab …

Objective To assess non-inferiority of sc to iv CT-P13 in RA. Methods Patients with active RA
and inadequate response to MTX participated in this phase I/III double-blind study at 76 …

CT-P13 is the first subcutaneous infliximab molecule approved for the management of
inflammatory bowel disease (IBD). Compared to intravenous therapy, SC infliximab offers a …

Subcutaneous infliximab recently received approval for the treatment of various immune-
mediated inflammatory diseases in Europe, following pivotal clinical trials in patients with …

Biosimilars are biological agents that effectively replicate original reference products. The
main driver of their development is the promise of bringing competition into the marketplace …

The biosimilar concept is now well established. Clinical data accumulated pre-and post-
approval have supported biosimilar uptake, in turn stimulating competition in the biologics …

Introduction Biologic drugs have significantly improved the treatment of ulcerative colitis
(UC) and Crohn's disease (CD). However, the availability of these drugs is limited by their …

BACKGROUND Tumor necrosis factor-alpha inhibitors, including infliximab and
adalimumab, are effective medical treatments for perianal fistulising Crohn's disease (CD) …